AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BLACKSTONE MINERALS LTD

0.039

0.000

Volume:572.80K

Turnover:22.41K

Market Cap:67.06M

PE:-3.12

High:0.040

Open:0.039

Low:0.039

Close:0.039

52wk High:0.086

52wk Low:0.028

Shares:1.72B

Float Shares:1.38B

Volume Ratio:0.50

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.013

EPS(LYR):-0.016

ROE:-28.74%

ROA:-16.85%

PB:0.73

PE(LYR):-2.41

Loading ...

Overview Company News Filings

Should Boston Scientific’s Shift Toward Capital Spending and External Innovation Require Action From (BSX) Investors?

Simply Wall St.

Boston Scientific (BSX) Rebounds Sharply, Is The Stock Still A Bargain?

Simply Wall St.

Resmed Inc Stock (RMD) Moved Up by 3.01% on Aug 10: Key Drivers Unveiled

Why Boston Scientific (BSX) Is Up 5.6% After Mixed Q2, Recall News And Guidance Update

Simply Wall St.

Boston Scientific (BSX) Stock Ignores Margin Strength As Growth Outlook Softens

Simply Wall St.

Boston Scientific's Watchman Slowdown Raises Utilization Questions, Oppenheimer Says

MT Newswires Live

Boston Scientific Lowered Full-Year Guidance on Headwinds in Electrophysiology, Watchman Portfolios, RBC Says

MT Newswires Live

GUIDANCE: (BSX) Boston Scientific Expects 2026 Adjusted EPS Range $3.28 to $3.32, vs. FactSet Est of $3.36

MT Newswires Live

Boston Scientific (BSX) Recalls Rapid Refill Injection System Over Syringe Detachment Risk

Simply Wall St.

Boston Scientific Has Underappreciated Growth Drivers, UBS Says

MT Newswires Live

Boston Scientific Continues to See Competitive Pressures, Oppenheimer Says

MT Newswires Live

Boston Scientific (BSX) Recalls Endoscopy Devices, Is The Stock A Bargain?

Simply Wall St.

How Boston Scientific’s 2026 Guidance Cut and Pump Recall At Boston Scientific (BSX) Has Changed Its Investment Story

Simply Wall St.

Is Boston Scientific (BSX) Undervalued Following Its Russell Growth Index Removal?

Simply Wall St.

Australia's Anson Resources Gains Most in a Month on U.S Lithium Operations Approval

ASX Penny Stocks To Watch In July 2026

Simply Wall St.

How Softer 2026 Guidance and EP Share Shifts At Boston Scientific (BSX) Has Changed Its Investment Story

Simply Wall St.

Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance

Simply Wall St.

Is Boston Scientific (BSX) Quietly Rebalancing From Structural Heart To Coronary Strength?

Simply Wall St.

Blackstone Minerals Ltd-Key Consultants Appointed as Mankayan Pfs Gains Moment

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BSX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BSX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BSX.AU\",,,,,undefined,":{"symbol":"BSX.AU","market":"AU","secType":"STK","nameCN":"BLACKSTONE MINERALS LTD","latestPrice":0.039,"timestamp":1787292720000,"preClose":0.039,"halted":0,"volume":572797,"delay":0,"changeRate":0,"nameEN":"BLACKSTONE MINERALS LTD","floatShares":1378369438,"shares":1719359861,"eps":-0.012512,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-21 16:12:00 AEST","open":0.039,"high":0.04,"low":0.039,"amount":22409,"amplitude":0.025641,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.012512,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.039,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.503747166917955,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BSX.AU","preClose":0.039,"auctionPrice":0.039,"auctionVolume":385214,"auctionTime":1787519707069,"referenceTime":1787308204093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787519707069}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BSX.AU\",,,,,undefined,":{"symbol":"BSX.AU","floatShares":1378369438,"roa":"-16.85%","roe":"-28.74%","lyrEps":-0.01616,"volumeRatio":0.503747166917955,"shares":1719359861,"dividePrice":0,"high":0.04,"amplitude":0.025641,"preClose":0.039,"low":0.039,"week52Low":0.028,"pbRate":"0.73","psRate":"-68.34","week52High":0.086,"institutionHeld":0,"latestPrice":0.039,"eps":-0.012512,"divideRate":0,"volume":572797,"delay":0,"ttmEps":-0.012512,"open":0.039,"prevYearClose":0.055,"prevWeekClose":0.039,"prevMonthClose":0.039,"prevQuarterClose":0.033,"fiveDayClose":0.039,"twentyDayClose":0.043,"sixtyDayClose":0.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BSX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BSX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BSX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661721736","title":"Should Boston Scientific’s Shift Toward Capital Spending and External Innovation Require Action From (BSX) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661721736","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661721736?lang=en_us&edition=fundamental","pubTime":"2026-08-23 08:32","pubTimestamp":1787445157,"startTime":"0","endTime":"0","summary":"Boston Scientific recently shifted its capital budget above its research budget for the first time in fifteen years, while planning seven new product launches and pursuing run-rate savings from cost programs to restore growth amid competitive pressure in Electrophysiology and softer WATCHMAN revenues.\nAn interesting twist is that two of the seven growth-driving launches are coming from outside Boston Scientific’s own labs, underscoring a greater reliance on external innovation alongside...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/should-boston-scientifics-shift-toward-capital-spending-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/should-boston-scientifics-shift-toward-capital-spending-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2506951958.HKD","LU1791710400.SGD","LU1291159041.SGD","LU1153585028.USD","LU0077335932.USD","LU2112291526.USD","LU0432979614.USD","SG9999013999.USD","LU0345769128.USD","LU2506952097.USD","BK4504","LU0823416689.USD","LU0114720955.EUR","BSX.AU","LU0353189680.USD","BK4581","LU0823417653.USD","LU0950375773.USD","LU2491050154.USD","LU0138981039.USD","ISBC","BK7095","LU2362541273.HKD","LU1989771016.USD","SGXZ57979304.SGD","LU0353189763.USD","LU1366192091.USD","LU2244417387.USD","LU1023059063.AUD","LU1989764664.SGD","LU2362541513.USD","LU0267386448.USD","IE00BJJMRZ35.SGD","LU0823417737.USD","LU2265009873.SGD","SG9999001176.USD","IE00BFTCPJ56.SGD","LU0122379950.USD","LU0882574055.USD","LU0266013472.USD","LU1989764748.USD","BK4211","BSX","LU2506952170.USD","LU1720051108.HKD","IE0002141913.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0528227936.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661230609","title":"Boston Scientific (BSX) Rebounds Sharply, Is The Stock Still A Bargain?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661230609","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661230609?lang=en_us&edition=fundamental","pubTime":"2026-08-21 05:21","pubTimestamp":1787260916,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) is drawing investor attention after its recent share move, with the stock closing at $52.01 on 18 August 2026. That price shift puts fresh focus on how its medical device business supports current valuation.\nSee our latest analysis for Boston Scientific.\nOver the past month Boston Scientific has seen a strong 30 day share price return of 18.83%, although the share price is still down 45.08% year to date and the 1 year total shareholder return is down 50.96%. This...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-rebounds-sharply-is-the-stock-still-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-rebounds-sharply-is-the-stock-still-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1791710582.SGD","LU0345769128.USD","LU0238689110.USD","LU2242649171.HKD","LU0225283273.USD","LU0353189763.USD","LU0267386448.USD","LU0266013472.USD","LU1989771016.USD","LU0882574055.USD","LU1291159041.SGD","SG9999001176.USD","LU2491049909.HKD","LU0432979614.USD","LU1366192091.USD","LU2087625088.SGD","LU0114720955.EUR","LU2506951958.HKD","LU2244417387.USD","LU2491050071.SGD","LU1804176565.USD","BK4581","LU1989772840.SGD","IE00BJJMRZ35.SGD","LU2362541273.HKD","LU0823417653.USD","IE00BJT1NW94.SGD","SG9999013999.USD","LU2265009873.SGD","SG9999001176.SGD","LU0823417737.USD","LU2506951875.HKD","BK7095","LU2324357040.USD","IE0002141913.USD","LU0353189680.USD","IE00B2B36J28.USD","LU0187121727.USD","LU0048584097.USD","LU1153585028.USD","BK4082","LU1989764748.USD","LU2506952170.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU2357305700.SGD","LU0122379950.USD","BSX.AU","BSX","LU1548497426.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658930168","title":"Resmed Inc Stock (RMD) Moved Up by 3.01% on Aug 10: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930168","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658930168?lang=en_us&edition=fundamental","pubTime":"2026-08-10 23:15","pubTimestamp":1786374931,"startTime":"0","endTime":"0","summary":"• ResMed reported strong recurring revenue from its AirSense platform and software ecosystem.\n• Clinical insights suggest GLP-1 drugs increase sleep apnea diagnosis rates and patient engagement.\n• ResMed solidified market share as its primary competitor faces ongoing regulatory constraints.","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262093058-market-movers-rmd-20260810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836757.USD","LU2362541513.USD","BSX.AU","BSX","ISUL","IE0002141913.USD","LU0070302665.USD","SG9999001176.USD","LU0011850046.USD","LU0048584097.USD","BK4567","LU1093756325.SGD","LU2087625088.SGD","LU1974910355.USD","RMD.AU","LU0267386448.USD","LU1989771016.USD","ISRG","LU0432979614.USD","LU0225283273.USD","LU0114720955.EUR","LU2491049909.HKD","LU2362540622.SGD","LU0353189763.USD","IE00BFXG0V08.USD","FXH","EKG","LGHT","LU0528227936.USD","BK4533","LU1791710400.SGD","LU2177674079.SGD","LU2491050071.SGD","IHI","LU0122379950.USD","LU1951198990.SGD","LU0238689110.USD","LU2008162690.USD","LU2063271972.USD","LU2265009873.SGD","IHF","BK7007","LU0823417653.USD","LU1093756168.USD","HUM.AU","LU2106854487.HKD","SG9999001176.SGD","RMD","HUM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656485333","title":"Why Boston Scientific (BSX) Is Up 5.6% After Mixed Q2, Recall News And Guidance Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656485333","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656485333?lang=en_us&edition=fundamental","pubTime":"2026-08-02 23:17","pubTimestamp":1785683857,"startTime":"0","endTime":"0","summary":"In late July 2026, Boston Scientific reported second-quarter results showing sales rising to US$5,442 million and net income reaching US$907 million, alongside updated guidance calling for 2026 reported net sales growth of about 5.5% to 6.5% and third-quarter growth of about 3% to 5% versus the prior year.\nAt the same time, the company issued a voluntary Class II recall of its Rapid Refill Continuous Injection System due to syringe connection risks, highlighting ongoing product quality and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/why-boston-scientific-bsx-is-up-56-after-mixed-q2-recall-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/why-boston-scientific-bsx-is-up-56-after-mixed-q2-recall-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0122379950.USD","IE00B4R5TH58.HKD","LU2244417387.USD","LU1989772923.USD","LU1023059063.AUD","LU1989771016.USD","IE00BJJMRZ35.SGD","BK4581","LU0138981039.USD","LU1057294990.SGD","LU1989764748.USD","LU0267386448.USD","LU0823417653.USD","LU0353189680.USD","SGXZ57979304.SGD","LU1366192091.USD","LU1989764664.SGD","LU1989772840.SGD","LU0238689110.USD","LU0345769631.USD","LU2357305700.SGD","LU1791710400.SGD","SG9999001176.SGD","BK4588","LU0823416689.USD","IE0002141913.USD","LU2362541273.HKD","BSX","LU0077335932.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","SG9999013999.USD","BK4504","LU0353189763.USD","LU0048584097.USD","LU2242649171.HKD","LU0187121727.USD","LU1720051017.SGD","LU2324357040.USD","BK7095","BSX.AU","LU2506951958.HKD","IE00BJT1NW94.SGD","LU2506951875.HKD","LU0950375773.USD","LU0266013472.USD","LU1718418525.SGD","IE00B2B36J28.USD","LU1061106388.HKD","LU0251132253.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655835586","title":"Boston Scientific (BSX) Stock Ignores Margin Strength As Growth Outlook Softens","url":"https://stock-news.laohu8.com/highlight/detail?id=2655835586","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655835586?lang=en_us&edition=fundamental","pubTime":"2026-07-31 15:21","pubTimestamp":1785482500,"startTime":"0","endTime":"0","summary":"Boston Scientific stock barely flinched after earnings, slipping only 0.1% and leaving shares roughly flat over the past week and month despite a sharp 18.6% decline over the last 90 days. The market is treating this quarter as business as usual. The numbers suggest something more important is happening inside the income statement.\nThe core story this quarter is margins. Adjusted gross margin reached 70.3% and adjusted operating margin hit 28.4%, both higher than a year ago, while trailing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-stock-ignores-margin-strength-as-growt","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-stock-ignores-margin-strength-as-growt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1989771016.USD","BSX.AU","BK4588","LU2087625088.SGD","LU0353189763.USD","LU0528227936.USD","LU1548497426.USD","LU2362540622.SGD","LU1718418525.SGD","BK4581","LU1153585028.USD","LU0345769128.USD","LU1983299246.USD","LU1291159041.SGD","BK4082","LU0122379950.USD","LU2112291526.USD","BK7095","LU2242649171.HKD","SG9999013999.USD","LU0238689110.USD","LU0432979614.USD","LU1989764664.SGD","LU1720051017.SGD","LU0267386448.USD","SGXZ57979304.SGD","LU0187121727.USD","LU2491049909.HKD","LU1791710400.SGD","LU0823417737.USD","LU1061106388.HKD","LU2357305700.SGD","LU2506951875.HKD","LU0345769631.USD","LU1804176565.USD","LU2506952097.USD","LU2362541273.HKD","IE0002141913.USD","LU0077335932.USD","BK4585","LU0251132253.USD","LU0950375773.USD","LU2506951958.HKD","LU2491050071.SGD","LU1989764748.USD","LU0138981039.USD","LU1989772840.SGD","BSX","IE00B4R5TH58.HKD","LU0011850046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655021328","title":"Boston Scientific's Watchman Slowdown Raises Utilization Questions, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655021328","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655021328?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:55","pubTimestamp":1785430539,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) guidance cut was driven by weakness in its Watchman and electrophysiology or EP businesses, with the gap versus initial long-range targets widening into 2027, Oppenheimer said ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0114720955.EUR","LU1989764748.USD","LU0138981039.USD","BK4585","LU0266013472.USD","LU1791710400.SGD","LU0238689110.USD","LU2506952097.USD","LU0011850046.USD","LU1804176565.USD","IE00BFTCPJ56.SGD","LU0187121727.USD","SG9999013999.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU1023059063.AUD","LU1983299246.USD","BK4504","LU0345769631.USD","LU2112291526.USD","LU2491050154.USD","LU2491049909.HKD","LU0077335932.USD","LU0267386448.USD","LU0823416689.USD","LU1989772840.SGD","BK4588","LU0225283273.USD","LU2506952170.USD","LU1791710582.SGD","LU1989764664.SGD","BSX.AU","LU1153585028.USD","LU0528227936.USD","LU1548497426.USD","LU2362541273.HKD","LU2265009873.SGD","SGXZ57979304.SGD","LU2506951875.HKD","BK4082","LU0823417653.USD","LU1989771016.USD","IE0009355771.USD","LU1057294990.SGD","LU2324357040.USD","OPY","LU2362540622.SGD","IE00B2B36J28.USD","BSX","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655804502","title":"Boston Scientific Lowered Full-Year Guidance on Headwinds in Electrophysiology, Watchman Portfolios, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655804502","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655804502?lang=en_us&edition=fundamental","pubTime":"2026-07-30 23:57","pubTimestamp":1785427033,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year guidance, which was largely expected given known headwinds in its Electrophysiology and Watchman po","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4504","LU0823417737.USD","LU2357305700.SGD","SG9999001176.SGD","IE0009355771.USD","LU1061106388.HKD","LU1548497426.USD","LU0353189763.USD","LU0187121727.USD","BK4588","LU0077335932.USD","LU0353189680.USD","SG9999001176.USD","LU1023059063.AUD","LU2506952170.USD","LU2506951875.HKD","LU2244417387.USD","LU0345769631.USD","LU0048584097.USD","LU1791710582.SGD","IE00BFTCPJ56.SGD","LU2506951958.HKD","BSX","LU1057294990.SGD","LU0823416689.USD","BSX.AU","LU0823417653.USD","LU2491049909.HKD","LU0882574055.USD","LU1720051017.SGD","LU1791710400.SGD","IE00B2B36J28.USD","LU0011850046.USD","LU1983299246.USD","LU0238689110.USD","LU1153585028.USD","LU0345769128.USD","LU2506952097.USD","LU1804176565.USD","LU1989764664.SGD","LU2324357040.USD","LU2362540622.SGD","BK4581","BK4082","LU1291159041.SGD","LU1720051108.HKD","LU2491050071.SGD","SGXZ57979304.SGD","LU2242649171.HKD","LU0138981039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655869445","title":"GUIDANCE: (BSX) Boston Scientific Expects 2026 Adjusted EPS Range $3.28 to $3.32, vs. FactSet Est of $3.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2655869445","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655869445?lang=en_us&edition=fundamental","pubTime":"2026-07-29 18:32","pubTimestamp":1785321171,"startTime":"0","endTime":"0","summary":"GUIDANCE: (BSX) Boston Scientific Expects 2026 Adjusted EPS Range $3.28 to $3.32, vs. FactSet Est of $3.36","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BSX","BSX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655783839","title":"Boston Scientific (BSX) Recalls Rapid Refill Injection System Over Syringe Detachment Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2655783839","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655783839?lang=en_us&edition=fundamental","pubTime":"2026-07-29 02:14","pubTimestamp":1785262497,"startTime":"0","endTime":"0","summary":"Boston Scientific has issued a voluntary Class II recall of its Rapid Refill Continuous Injection System.\nThe recall is linked to a risk that syringes may loosen or detach, which could affect device performance and procedural outcomes.\nThe action covers a large number of units distributed in the US and international markets.\n\nFor investors watching Boston Scientific, ticker NYSE:BSX, this recall comes amid a mixed share performance backdrop. The stock closed at $45.51, with returns up 4.0%...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-rapid-refill-injection-system","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-rapid-refill-injection-system","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0528227936.USD","LU1989772923.USD","LU0077335932.USD","LU1989764748.USD","SG9999001176.USD","LU2112291526.USD","BK4585","IE00BFTCPJ56.SGD","LU0823417653.USD","LU0122379950.USD","LU1023059063.AUD","LU2357305700.SGD","BK4504","LU2506952097.USD","LU0048584097.USD","LU1989772840.SGD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU0345769631.USD","IE0009355771.USD","LU1791710582.SGD","LU2362541273.HKD","SGXZ57979304.SGD","BSX.AU","BSX","LU0950375773.USD","LU0345769128.USD","LU2244417387.USD","LU2506951875.HKD","LU0225283273.USD","IE00B4R5TH58.HKD","LU1804176565.USD","LU1791710400.SGD","LU2491050071.SGD","SG9999001176.SGD","LU0353189763.USD","LU1291159041.SGD","LU0138981039.USD","LU0353189680.USD","LU0187121727.USD","LU1061106388.HKD","LU2242649171.HKD","LU0823417737.USD","LU2506951958.HKD","LU0823416689.USD","BK4581","LU1548497426.USD","LU0432979614.USD","LU1983299246.USD","LU1718418525.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655884305","title":"Boston Scientific Has Underappreciated Growth Drivers, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655884305","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655884305?lang=en_us&edition=fundamental","pubTime":"2026-07-29 02:10","pubTimestamp":1785262202,"startTime":"0","endTime":"0","summary":"Boston Scientific  has underappreciated growth drivers beyond its electrophysiology and Watchman franchises that should support continued high-single-digit organic growth, UBS said in a note Tuesday.The firm pointed to coronary intravascular lithotripsy and renal denervation products expected in 2027 and 2028, representing a combined $2.5 billion served market, along with Empower leadless pacemaker launch in 2027 that could help the company gain share in a structurally higher-growth cardiac rhythm management market.UBS said management's lowered growth outlook for electrophysiology and Watchman is already reflected in Street models, giving the company room to shift focus toward other high-growth areas.The firm added that current share pricing implies sales declines through 2029, versus its own and consensus estimates for high-single-digit growth, suggesting the recent pullback is overdone.UBS assumed coverage of Boston Scientific with a buy rating and $74 price target.Price: 46.48, Chan","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0528227936.USD","LU2362541513.USD","LU1989772923.USD","LU2087625088.SGD","BK4082","SG9999013999.USD","LU1989764748.USD","BK7095","LU2265009873.SGD","BK4585","LU0823417653.USD","LU0122379950.USD","LU1023059063.AUD","LU2506952097.USD","LU0048584097.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0345769631.USD","LU1989771016.USD","IE0009355771.USD","SGXZ57979304.SGD","BSX.AU","BSX","LU0950375773.USD","LU0345769128.USD","LU2244417387.USD","LU0225283273.USD","IE00B4R5TH58.HKD","LU1804176565.USD","LU0114720955.EUR","LU1791710400.SGD","LU2491050071.SGD","SG9999001176.SGD","LU2324357040.USD","LU0251132253.USD","LU1057294990.SGD","LU1291159041.SGD","LU1720051108.HKD","LU0138981039.USD","LU0353189680.USD","LU0187121727.USD","LU0882574055.USD","IE00BJT1NW94.SGD","LU2242649171.HKD","LU0823417737.USD","LU2506951958.HKD","LU0823416689.USD","LU0238689110.USD","LU0432979614.USD","LU1366192091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654049399","title":"Boston Scientific Continues to See Competitive Pressures, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2654049399","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654049399?lang=en_us&edition=fundamental","pubTime":"2026-07-27 23:00","pubTimestamp":1785164401,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) continues to see competitive pressures that could have weighed on the company's Q2 results, Oppenheimer said in a Monday note.The company is set to release its Q2 results on We","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1023059063.AUD","BK4588","LU1718418525.SGD","LU0345769631.USD","LU2491049909.HKD","LU1291159041.SGD","LU1989764748.USD","BK7095","IE00BJT1NW94.SGD","LU0823416689.USD","LU2357305700.SGD","LU0251132253.USD","LU0823417653.USD","LU1720051108.HKD","LU1057294990.SGD","LU1366192091.USD","LU1804176565.USD","LU2506951875.HKD","LU2244417387.USD","LU0353189763.USD","LU0345769128.USD","LU2242649171.HKD","BSX","LU1989772840.SGD","IE00B4R5TH58.HKD","LU0432979614.USD","LU0353189680.USD","BK4581","SGXZ57979304.SGD","LU0528227936.USD","OPY","LU2112291526.USD","LU1061106388.HKD","LU0048584097.USD","LU0122379950.USD","LU1791710400.SGD","LU2265009873.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0823417737.USD","BK4127","BSX.AU","SG9999001176.SGD","LU0882574055.USD","LU2506952097.USD","LU0011850046.USD","LU1983299246.USD","BK4585","LU2362540622.SGD","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652843352","title":"Boston Scientific (BSX) Recalls Endoscopy Devices, Is The Stock A Bargain?","url":"https://stock-news.laohu8.com/highlight/detail?id=2652843352","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652843352?lang=en_us&edition=fundamental","pubTime":"2026-07-17 22:25","pubTimestamp":1784298331,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) is under scrutiny after a series of voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices, prompted by potential sterile packaging breaches affecting tens of thousands of units globally.\nSee our latest analysis for Boston Scientific.\nThe recalls arrive after a period of sharp share price weakness, with Boston Scientific’s stock down 30.53% on a 3 month share price return basis and 52.89% year to date. The 1 year total shareholder return has...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-endoscopy-devices-is-the-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-endoscopy-devices-is-the-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0225283273.USD","IE00BJT1NW94.SGD","LU0950375773.USD","LU1057294990.SGD","LU2362541513.USD","LU0251132253.USD","SGXZ57979304.SGD","LU2362540622.SGD","IE00B2B36J28.USD","LU2357305700.SGD","IE0002141913.USD","LU2506952170.USD","LU2491050071.SGD","LU2242649171.HKD","IE0009355771.USD","LU0432979614.USD","IE00BFTCPJ56.SGD","LU0345769128.USD","BSX","BK4581","LU0048584097.USD","LU1718418525.SGD","LU0187121727.USD","BK4585","LU2112291526.USD","LU1804176565.USD","LU1989771016.USD","BSX.AU","LU1061106388.HKD","LU1548497426.USD","LU0266013472.USD","LU2506951875.HKD","LU2324357040.USD","BK4588","LU1791710400.SGD","LU0823416689.USD","LU1153585028.USD","LU2491050154.USD","LU0353189680.USD","LU1989764748.USD","LU2506952097.USD","LU0011850046.USD","LU1989772840.SGD","LU1989772923.USD","LU2265009873.SGD","LU1366192091.USD","LU2087625088.SGD","LU0122379950.USD","LU1720051017.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650522331","title":"How Boston Scientific’s 2026 Guidance Cut and Pump Recall At Boston Scientific (BSX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2650522331","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650522331?lang=en_us&edition=fundamental","pubTime":"2026-07-12 04:28","pubTimestamp":1783801734,"startTime":"0","endTime":"0","summary":"In early July 2026, Boston Scientific voluntarily recalled a single Intera Oncology INTERA 3000 Hepatic Artery Infusion Pump (Class II, Serial Number 20175) in the US after identifying potential leakage from the pump through the catheter, with the recall now classified as completed.\nA separate earnings update saw management cut 2026 guidance amid weakness in WATCHMAN, Electrophysiology, and Urology, while expressing confidence that upcoming product launches could support results in 2027 and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/how-boston-scientifics-2026-guidance-cut-and-pump-recall-at","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/how-boston-scientifics-2026-guidance-cut-and-pump-recall-at","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1989764748.USD","LU0345769128.USD","LU2362541273.HKD","BK4504","LU2506951875.HKD","LU0225283273.USD","LU2362540622.SGD","LU1720051108.HKD","LU0432979614.USD","LU1804176565.USD","LU2491049909.HKD","LU1989772923.USD","LU0353189763.USD","BK4581","LU1366192091.USD","LU2087625088.SGD","BK4082","SG9999013999.USD","IE0002141913.USD","IE0009355771.USD","LU0122379950.USD","LU1061106388.HKD","LU2265009873.SGD","IE00B4R5TH58.HKD","BK4585","LU0267386448.USD","LU1057294990.SGD","LU1153585028.USD","LU1291159041.SGD","BSX.AU","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0266013472.USD","LU0823417653.USD","LU1791710400.SGD","LU2491050154.USD","LU0011850046.USD","LU1983299246.USD","LU0823417737.USD","LU1023059063.AUD","LU2506952170.USD","LU2244417387.USD","LU0882574055.USD","LU0238689110.USD","LU2506952097.USD","SGXZ57979304.SGD","LU0950375773.USD","IE00BJT1NW94.SGD","LU0114720955.EUR","BSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650294186","title":"Is Boston Scientific (BSX) Undervalued Following Its Russell Growth Index Removal?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650294186","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650294186?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:43","pubTimestamp":1783673028,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) has recently been dropped from several Russell growth benchmarks, a broad index reshuffle that can affect how index funds hold the stock and may change short term trading volumes.\nSee our latest analysis for Boston Scientific.\nOver the past year Boston Scientific has shifted from strong multi year gains to clear selling pressure, with the share price at $44.99 and a 90 day share price return down 27.19% and a 1 year total shareholder return down 56.68%. Recent index...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/is-boston-scientific-bsx-undervalued-following-its-russell-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/is-boston-scientific-bsx-undervalued-following-its-russell-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B4R5TH58.HKD","LU0353189763.USD","LU1983299246.USD","LU1057294990.SGD","LU0345769631.USD","LU0225283273.USD","LU2506952170.USD","BK4585","LU2112291526.USD","LU0528227936.USD","BSX.AU","LU2087625088.SGD","SG9999001176.USD","LU1989764664.SGD","LU1291159041.SGD","LU2265009873.SGD","LU2362540622.SGD","LU2491050071.SGD","LU1720051108.HKD","LU2242649171.HKD","LU0251132253.USD","LU2362541273.HKD","LU0238689110.USD","LU2506951958.HKD","LU2506951875.HKD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4504","LU1548497426.USD","IE00BJJMRZ35.SGD","LU2491050154.USD","LU0823416689.USD","BK4082","LU1989772923.USD","BK4581","LU0950375773.USD","BSX","LU0011850046.USD","LU2244417387.USD","BK4588","LU0882574055.USD","LU0345769128.USD","LU0267386448.USD","LU0823417653.USD","LU0114720955.EUR","SG9999001176.SGD","LU1366192091.USD","LU1989771016.USD","LU1791710582.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650790572","title":"Australia's Anson Resources Gains Most in a Month on U.S Lithium Operations Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2650790572","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650790572?lang=en_us&edition=fundamental","pubTime":"2026-07-10 10:27","pubTimestamp":1783650461,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Anson Resources gains most in a month on U.S lithium operations approval** Shares of Australia's Anson ResourcesASN.AXrise as much as 11.63% to A$0.048inbiggest intraday pct gainin ne","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nL6N43C04M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","BSX.AU","ASN.AU","BK7504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650901170","title":"ASX Penny Stocks To Watch In July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901170","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650901170?lang=en_us&edition=fundamental","pubTime":"2026-07-10 10:05","pubTimestamp":1783649103,"startTime":"0","endTime":"0","summary":"The Australian stock market is experiencing a flat open, with modest movements not quite enough to propel the ASX 200 into positive territory, despite recoveries in the U.S. and Europe. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing opportunities for investors seeking growth at lower price points. By focusing on those with strong financials and a clear growth trajectory, these stocks can present valuable prospects for those looking to explore this...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3031000-choice2-main-header/1585186655644","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3031000-choice2-main-header/1585186655644"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-gwa/gwa-group-shares/news/asx-penny-stocks-to-watch-in-july-2026-4","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-gwa/gwa-group-shares/news/asx-penny-stocks-to-watch-in-july-2026-4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BSX.AU","BK7062","BK7121","GWA.AU","BK7012","QAL.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645510044","title":"How Softer 2026 Guidance and EP Share Shifts At Boston Scientific (BSX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2645510044","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645510044?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:20","pubTimestamp":1782109207,"startTime":"0","endTime":"0","summary":"Earlier in 2026, Boston Scientific reported solid Q1 results with 11.6% year-over-year revenue growth, but its initial 2026 guidance came in below market expectations and highlighted slowing momentum in its electrophysiology business.\nThe electrophysiology slowdown, where Medtronic appears to be gaining share, raises questions about Boston Scientific’s competitive positioning in a segment that has been an important growth contributor.\nWe’ll now examine how softer guidance and...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/how-softer-2026-guidance-and-ep-share-shifts-at-boston-scien","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/how-softer-2026-guidance-and-ep-share-shifts-at-boston-scien","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0114720955.EUR","LU1989764748.USD","SG9999001176.USD","LU2362541513.USD","LU0138981039.USD","LU0353189680.USD","LU2087625088.SGD","BK4585","LU0266013472.USD","IE0002141913.USD","LU2506952097.USD","BK7095","LU0011850046.USD","LU1804176565.USD","IE00BFTCPJ56.SGD","LU0187121727.USD","IE00B4R5TH58.HKD","LU0251132253.USD","IE00BJJMRZ35.SGD","LU2244417387.USD","EP","LU1023059063.AUD","LU2242649171.HKD","BK4504","LU0345769631.USD","LU2112291526.USD","LU0432979614.USD","LU2491049909.HKD","LU0345769128.USD","LU0823416689.USD","LU0353189763.USD","LU1791710582.SGD","LU1989764664.SGD","BSX.AU","LU1153585028.USD","LU1548497426.USD","BK4213","LU1989772923.USD","LU2362541273.HKD","LU2265009873.SGD","SGXZ57979304.SGD","LU2506951875.HKD","BK4082","LU0823417653.USD","LU1366192091.USD","LU1989771016.USD","LU1720051108.HKD","LU2491050071.SGD","BSX","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644065423","title":"Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2644065423","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644065423?lang=en_us&edition=fundamental","pubTime":"2026-06-20 02:48","pubTimestamp":1781894927,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment.\nSee our latest analysis for Boston Scientific.\nAt a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-stock-could-be-542-undervalued-after-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-stock-could-be-542-undervalued-after-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1718418525.SGD","LU1989764664.SGD","LU1291159041.SGD","LU0266013472.USD","LU0950375773.USD","LU0353189680.USD","LU2265009873.SGD","BK4082","SGXZ57979304.SGD","LU0048584097.USD","LU0114720955.EUR","IE0009355771.USD","LU0238689110.USD","LU2506951875.HKD","IE00BFTCPJ56.SGD","LU2506952170.USD","LU0345769128.USD","LU2112291526.USD","LU1989771016.USD","IE0002141913.USD","LU0011850046.USD","LU0345769631.USD","LU2362540622.SGD","LU0267386448.USD","BSX","LU0225283273.USD","BK4581","LU0187121727.USD","LU1791710582.SGD","BK4585","LU2357305700.SGD","LU1989772923.USD","LU2362541273.HKD","LU1023059063.AUD","LU1989764748.USD","LU2244417387.USD","LU2324357040.USD","LU0823417737.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU2087625088.SGD","LU0138981039.USD","LU1061106388.HKD","LU2506951958.HKD","LU1989772840.SGD","BSX.AU","LU1153585028.USD","LU1057294990.SGD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640341311","title":"Is Boston Scientific (BSX) Quietly Rebalancing From Structural Heart To Coronary Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2640341311","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640341311?lang=en_us&edition=fundamental","pubTime":"2026-06-04 13:28","pubTimestamp":1780550897,"startTime":"0","endTime":"0","summary":"In recent weeks, Boston Scientific reported solid year-on-year revenue growth but issued softer guidance, as management flagged slowing U.S. Watchman device sales and intensifying cardiac market competition, prompting some analysts to downgrade the company. \nAt the same time, the company announced positive pivotal FRACTURE IDE trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter, highlighting how strengths in its coronary portfolio may balance weakness in parts of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/is-boston-scientific-bsx-quietly-rebalancing-from-structural","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/is-boston-scientific-bsx-quietly-rebalancing-from-structural","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1989764748.USD","LU0345769128.USD","LU2362541273.HKD","LU1989771016.USD","LU2242649171.HKD","LU2357305700.SGD","BK4504","LU2506951875.HKD","LU0251132253.USD","LU0225283273.USD","LU2362540622.SGD","LU1720051108.HKD","LU0048584097.USD","LU0432979614.USD","LU2491050071.SGD","SG9999001176.USD","LU1989772923.USD","BK4581","LU2087625088.SGD","BK4082","IE0002141913.USD","IE0009355771.USD","LU1989772840.SGD","LU1548497426.USD","LU0528227936.USD","LU0267386448.USD","LU0187121727.USD","LU0345769631.USD","LU1057294990.SGD","LU1153585028.USD","BSX.AU","IE00BFTCPJ56.SGD","LU0823417653.USD","LU1791710400.SGD","LU2491050154.USD","LU0011850046.USD","LU0077335932.USD","SG9999001176.SGD","LU1983299246.USD","LU1023059063.AUD","IE00B2B36J28.USD","LU1989764664.SGD","LU0823416689.USD","LU0882574055.USD","LU0950375773.USD","IE00BJT1NW94.SGD","LU2506951958.HKD","BSX","LU1718418525.SGD","LU0353189680.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640385960","title":"Blackstone Minerals Ltd-Key Consultants Appointed as Mankayan Pfs Gains Moment","url":"https://stock-news.laohu8.com/highlight/detail?id=2640385960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640385960?lang=en_us&edition=fundamental","pubTime":"2026-06-02 06:21","pubTimestamp":1780352495,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUE7KGFVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","BSX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}